AI Meets Value-Based Care: Cleerly and Cardiac Care Alliance Join Forces to Revolutionize Heart Disease Detection
DENVER--(BUSINESS WIRE)-- Cleerly, the leader in cardiovascular imaging, and Cardiac Care Alliance, leader in value-based cardiovascular care solutions, today announced a strategic partnership to enhance cardiovascular care delivery across the healthcare ecosystem. This collaboration will integrate Cleerly's advanced AI-powered coronary artery assessment technology with Cardiac Care Alliance's cardiovascular care network.
This collaboration will integrate Cleerly's advanced AI-powered coronary artery assessment technology with Cardiac Care Alliance's cardiovascular care network.
Share
As part of this partnership, Cardiac Care Alliance's offering to payers and practices will include Cleerly's Artificial Intelligence–Quantitative Coronary Tomography (AI-QCT) technology. The goal is to ensure symptomatic patients undergo Cleerly's noninvasive assessment, when appropriate, prior to cardiac catheterization procedures, helping direct the right patients to the catheterization laboratory while avoiding unnecessary testing and associated costs for others. The initiative will launch initially with cardiology practices in Texas, with plans for broader implementation.
Cardiac Care Alliance improves access to care and reduces overall unnecessary spending through collaboration with cardiologists, primary care providers, patients, health systems, and payers, while Cleerly's AI-QCT technology provides comprehensive, standardized assessment of coronary artery disease based on noninvasive Cardiac Computed Tomography Angiography (CCTA). Studies comparing Cleerly's technology with invasive gold standards have demonstrated high accuracy in assessing the presence, extent, and composition of coronary atherosclerotic plaque, superior to consensus readings from Level 3 Expert Physician Readers 1.
"We're always seeking ways to expand access to life-saving heart care, and by combining our networks, both organizations can reach more providers and patients," said Prakash Patel, MD, CEO and Chairman of Cardiac Care Alliance. "This partnership represents our commitment to providing solutions that are both clinically effective and economically sustainable. Cardiovascular disease currently costs the US healthcare system approximately $233 billion annually, and is the most costly chronic condition in the US, roughly 11% of total healthcare expenditures 2. Delivering care that can provide early detection and guide clinical decisions to the right interventions to improve outcomes and reduce unnecessary costs, are critical to addressing this growing healthcare challenge."
"This collaboration with Cardiac Care Alliance marks Cleerly's first value-based care partnership, representing an important milestone in our mission to transform cardiovascular care," said Dr. James Min, founder and CEO of Cleerly. "By detecting coronary artery disease with greater precision and more accurately through noninvasive means, we can help guide personalized care decisions that improve outcomes while reducing healthcare costs. With cardiovascular costs projected to increase to over $1 trillion by 2035 as the population ages 3, and hospital readmissions for cardiac conditions among the most common and costly within Medicare 4, we're strongly focused on the fact that many cardiovascular conditions are treatable when caught early, potentially saving countless lives."
About Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.
About Cardiac Care Alliance
Cardiac Care Alliance is revolutionizing cardiovascular care through an innovative, integrated, and partnership-driven model. By empowering providers, payers, health systems, and patients with timely access to high-quality care, patient outcomes are improved while optimizing costs. This value-based approach prioritizes quality and measurable health improvements. Cardiac Care Alliance is committed to proactive, personalized, and patient-centered care models that make cardiovascular healthcare more seamless, accessible, and coordinated. Through strategic partnerships, the alliance enhances care delivery, drives better outcomes, and creates sustainable, cost-effective solutions. To learn more, visit: cardiaccarealliance.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J., June 05, 2025--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. "FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too," said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. "For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance." "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients," said Nicole Jacque, co-founder of FIP Global Cats. "Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP." Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About WedgewoodWedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit View source version on Contacts Jennifer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J.--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment." Share GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. 'FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too,' said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. 'For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance.' "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients,' said Nicole Jacque, co-founder of FIP Global Cats. 'Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP.' Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About Wedgewood Wedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit
WebMD
2 hours ago
- WebMD
The Right Way to Use AI to Interpret Medical Test Results
June 5, 2025 – It's a common situation today: You're anxiously awaiting the results of a medical test when – ding! – they land in your patient portal. You'll be looking at them before your doctor. You start reading, but the confusing jargon makes you more nervous. What's a tortuous colon? Is a 1-centimeter nodule on my thyroid big enough to worry about? Do I have cancer? Many people are now using artificial intelligence tools such as ChatGPT to decipher their test results while they wait to hear from their doctor. Some doctors see it as the next-gen version of asking Dr. Google, but on steroids. Just like an old-school internet search, the answers can range from highly accurate to not-so-helpful to misleading to terrifying. "Patients often do this and come in with conclusions, and sometimes those conclusions are appropriate based on what ChatGPT has recommended," says Karim Hanna, MD, an associate professor and program director of the University of South Florida's Family Medicine Residency Program. "But also, there are times where those conclusions need redirection or clarification for the patients so they're not misunderstanding the details." We asked doctors to spell out the pros and cons of using AI to interpret medical test results and share advice on the smartest ways to do it. What are the benefits of using AI to explain test results? AI is good at translating medical terms into understandable language. Test result reports aren't exactly patient-friendly. "I've been a physician for 20 years, and there are aspects of these radiology reports I don't understand because they're talking about the dye and the protocol, and that's very specific to a radiologist," says Ateev Mehrotra, MD, MPH, chair of the Department of Health Services, Policy and Practice at the Brown University School of Public Health and a researcher studying how AI can make test reports more understandable. "This is a document that was really directed to talk between doctors, or sometimes between radiologists." Say a report says you have a tortuous colon. It sounds horrific, but it just means your colon's twists and turns were hard to navigate. AI can clarify things like that. "If there's some verbiage that is kind of medical lingo, ChatGPT does a great job of bringing it to lay terms and explaining things to patients," says Hanna. Plain-language summaries help people digest results. One study found that people with cancer who received a CT scan report simplified by a large language model and checked by a radiologist understood their condition better than people who only received the original report. Another study found that patients better understood their pathology reports when they received an AI-generated summary. Some health systems, such as Stanford Medicine, are now using AI tools to help doctors explain test results to patients. Mehrotra expects more will follow. AI can ease panic – in some cases. Now that test results go straight to patients, sometimes before doctors see them, anxiety around test results is common, research shows. Mehrotra says AI tools could potentially decrease panicked calls to doctors by helping patients understand common findings and test results that are normal or low risk. " The hope is that more people will see their test results and say, 'Oh, it's OK,' and then be willing to wait for their doc for a couple days to respond, as opposed to having that panic," says Mehrotra. What are the downsides of using AI to explain test results? It can be wrong. AI is good, but it's not perfect. ChatGPT is 87%-94% accurate when it analyzes radiology reports, according to Harvard research, and about 97% accurate at interpreting pathology reports, according to a study in JAMA Network Open. Sometimes, AI tools such as ChatGPT generate hallucinations, presenting incorrect information as if it's true (and doing so in a confident way). Fact-check: First, click the supporting links to ensure the information comes from real sources. "There are times where it just makes up sources, and you try to find that source, and it's nowhere to be found," says Sirui Jiang, MD, PhD, a diagnostic radiology resident at University Hospitals Cleveland who studies AI. Once you verify a source exists, check its quality. Ideally, it's a peer-reviewed journal, a doctors' society, or a health system. Then, make sure the text says what the AI tool claims it does. The output isn't tailored to your situation. One drawback of ChatGPT for interpreting medical tests: It lacks context about the patient's medical history, according to research by Hanna and colleagues. When ChatGPT interprets one test in isolation, it might miss the big picture. "Let's say someone has a hemoglobin of 11," says Hanna. "That hemoglobin of 11 is, in theory, abnormal, and ChatGPT will report it as such, sometimes giving reasons that may be scary or concerning to patients." For example, ChatGPT might say that person needs to rule out colon cancer. But they may have had a hemoglobin of 11 for years, and this finding might not actually be new or concerning. "Take everything that ChatGPT gives you with a grain of salt," says Hanna. "The best person to give you recommendations on the results that they ordered is the physician that ordered said result because that clinician will at least have the wherewithal to get you to the right resource, even if it's beyond their capacity to handle that problem." If you're expecting bad news, should you wait to hear from your doctor? Before a high-stakes test, like a test to stage cancer, doctors and patients should make a plan to shorten the limbo period when a patient is alone with their results, says Howard Forman, MD, MBA, a professor of radiology and biomedical imaging at Yale University. "The first thing is to have foresight, both from the patient as well as the physician point of view, and an agreement about how you're going to handle new information," he says. "I think some physicians know that a patient is awaiting a very anxiety-provoking report, and in those situations, it's really useful to have an agreement that the doctor is going to be as anxious to see the results as you are and that they'll be in touch with you by MyChart in a few hours, or maybe by phone or maybe in person." Whether you choose to dive into the results early or not, at least you know how soon you will have a chance to ask questions. What should you tell AI about your test results? For the most helpful output, don't just copy and paste test results into an AI tool and hit send. Use prompt engineering – the art and science of creating prompts for best results. "If you're a patient and you are going to leverage these tools, then I usually suggest an acronym, C.A.R.E," says Hanna. Give the tool: Context, or background about yourself Action, a verb that describes what you want it to do Role to take on; in this case, an expert doctor Expectations for how complex the explanation will be For example, you could paste your results and add the following text: I am __. (Enter relevant background information, like your age, if you're comfortable with it, keeping in mind that these tools don't have the same security and privacy standards as medical records.) Assume the role of a _____. (Enter radiologist for an imaging test or pathologist for a tissue or fluid sample.) Please ____ (Identify the key findings in this report OR tell me what the most likely next steps would be OR simplify this report.) at a _____ language level. (Start with fourth grade. If you want more detail and complexity, go up to your highest education level.) Try a few variations and compare. "If you're going to do it, do it a few ways and see how consistent it is," says Mehrotra. "Three interpreted responses versus just one is probably going to be more helpful." Consider using an AI tool made for medical information and clinical data, such as Open Evidence. "It's trained on evidence-based medicine, essentially, so it's not just pulling from the internet; it's pulling from peer-reviewed articles," says Hanna. Whether patients use AI or not, radiologists and imaging specialists can help by writing reports in scientifically accurate yet understandable ways, says Forman. "The more that we can use terms that are clear, concise, and convey information in a manner that is useful to the clinicians and then the patients, the better it is," he says. How should you talk with your doctor about what ChatGPT told you? If you're concerned, call and ask to discuss your results as soon as possible. Be upfront about where you got your information. "If you're feeling guilty about using ChatGPT or any other way to interpret your test results, don't feel guilty, and don't hide it from the doctor," says Mehrotra. "Everyone's doing it." During the waiting game, it helps to remember that while most doctors are busy, they move fast in emergencies. "Patients may not be aware of that if there's something life-threatening on a radiology test, a laboratory test, a pathology test, that radiologist is calling at 2 a.m. or whatever time it is to a doctor to say, 'Look, there's a life-threatening issue here, call the patient, get them on board," says Mehrotra. "That is their responsibility."
